(Q36900261)

17 August 2017

title

Panitumumab monotherapy in patients with previously treated metastatic colorectal cancer (English)

1 reference

17 August 2017

1 reference

J Randolph Hecht

1

1 reference

17 August 2017

Amita Patnaik

2

1 reference

17 August 2017

Jordan Berlin

3

1 reference

17 August 2017

Alan Venook

4

1 reference

17 August 2017

Imtiaz Malik

5

1 reference

17 August 2017

Simon Tchekmedyian

6

1 reference

17 August 2017

Lynn Navale

7

1 reference

17 August 2017

Rafael G Amado

8

1 reference

17 August 2017

Neal J Meropol

9

1 reference

17 August 2017

language of work or name

English

0 references

publication date

1 September 2007

1 reference

17 August 2017

1 reference

17 August 2017

volume

110

1 reference

17 August 2017

issue

5

1 reference

17 August 2017

page(s)

980-988

1 reference

17 August 2017

cites work

Cancer statistics, 2006

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22915

7 January 2021

Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22915

7 January 2021

A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22915

7 January 2021

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22915

7 January 2021

Bevacizumab in Combination With Oxaliplatin, Fluorouracil, and Leucovorin (FOLFOX4) for Previously Treated Metastatic Colorectal Cancer: Results From the Eastern Cooperative Oncology Group Study E3200

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22915

7 January 2021

Untangling the ErbB signalling network

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22915

7 January 2021

Chemoprevention of breast cancer: a model for change

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22915

7 January 2021

The prognostic significance of proliferating cell nuclear antigen, epidermal growth factor receptor, and mdr gene expression in colorectal cancer.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22915

7 January 2021

Targeting signal transduction pathways in colorectal cancer--more than skin deep

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22915

7 January 2021

Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22915

7 January 2021

Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22915

7 January 2021

Functional transplant of megabase human immunoglobulin loci recapitulates human antibody response in mice

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22915

7 January 2021

Therapeutic potential of ABX-EGF: a fully human anti-epidermal growth factor receptor monoclonal antibody for cancer treatment

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22915

7 January 2021

Preclinical and clinical evaluations of ABX-EGF, a fully human anti-epidermal growth factor receptor antibody

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22915

7 January 2021

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22915

7 January 2021

Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22915

7 January 2021

Epidermal growth factor receptor inhibitors in colorectal cancer: it's time to get back on target

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22915

7 January 2021

Phase II trial of paclitaxel, carboplatin, and etoposide in advanced poorly differentiated neuroendocrine carcinoma: a Minnie Pearl Cancer Research Network Study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22915

7 January 2021

Inhibited growth of colon cancer carcinomatosis by antibodies to vascular endothelial and epidermal growth factor receptors

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22915

7 January 2021

A phase III randomized, open-label, controlled trial of chemotherapy and bevacizumab with or without panitumumab in the first-line treatment of patients with metastatic colorectal cancer.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22915

7 January 2021

Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22915

7 January 2021

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22915

7 January 2021

Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22915

7 January 2021

Epidermal growth factor receptor mutations, small-molecule kinase inhibitors, and non-small-cell lung cancer: current knowledge and future directions

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22915

7 January 2021

Somatic mutations of EGFR in colorectal cancers and glioblastomas

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22915

7 January 2021

Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22915

7 January 2021

KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22915

7 January 2021

Identifiers

DOI

10.1002/CNCR.22915

1 reference

17 August 2017

1 reference